On June 22, 2023, Bill C-47 received Royal Assent, introducing amendments to the Food and Drugs Act (FDA) concerning Natural Health Products (NHPs). These amendments extend the enforcement power of Health Canada by implementing provisions meant to “safeguard public health”. The key provisions, which take immediate effect, include:
Bill C-47 amends the definition of therapeutic products in the Food and Drugs Act (FDA) to remove the existing exemption for Natural Health Products from Vanessa’s Law within the NHPR. This means that existing provisions of the FDA, as described above, now apply equally to natural health products. However, the extent to which Health Canada will enforce these provisions is based on the safety risk of the product and that “these authorities would generally only be used when a serious health and/or safety risk is identified”. Of particular note, the amendments include fines of up to $5,000,000.00 CAD as a penalty for failing to comply with the provisions.
If you manufacture, distribute, sell, import, package, and/or label NHPs in Canada, we recommend you review the therapeutic product provisions and the NHPR to ensure your products are in compliance. dicentra can help facilitate this process with our full life-cycle product support services for Natural Health Products.
Contact dicentra today to learn about Bill C-47 and how it can impact your business.